Barnett et al. [44] found that, out of 47 tumors evaluable by IHC, 36% had PTEN loss which was associated with an increased relapse in high risk prostate cancer treated with chemotherapy followed by surgery. This evidence concerns the gene PTEN and prostate carcinoma.